A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT04242446. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Study identification
- NCT ID
- NCT04242446
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 505 participants
Conditions and interventions
Conditions
Interventions
- Bimekizumab Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 18, 2020
- Primary completion
- Apr 6, 2022
- Completion
- Feb 18, 2023
- Last update posted
- May 18, 2026
2020 – 2023
United States locations
- U.S. sites
- 28
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hs0003 50140 | Birmingham | Alabama | 35233 | — |
| Hs0003 50175 | Phoenix | Arizona | 85006 | — |
| Hs0003 50161 | Los Angeles | California | 90045 | — |
| Hs0003 50220 | San Diego | California | 92123 | — |
| Hs0003 50205 | North Miami Beach | Florida | 33162-4708 | — |
| Hs0003 50153 | Ormond Beach | Florida | 32174 | — |
| Hs0003 50141 | Tampa | Florida | 33613 | — |
| Hs0003 50210 | Atlanta | Georgia | 30309 | — |
| Hs0003 50280 | Watkinsville | Georgia | 30677 | — |
| Hs0003 50425 | Murray | Kentucky | 42071 | — |
| Hs0003 50198 | Beverly | Massachusetts | 01915 | — |
| Hs0003 50146 | Boston | Massachusetts | 02215 | — |
| Hs0003 50194 | Omaha | Nebraska | 68144 | — |
| Hs0003 50208 | Las Vegas | Nevada | 89148 | — |
| Hs0003 50137 | East Windsor | New Jersey | 08520 | — |
| Hs0003 50235 | New York | New York | 10003 | — |
| Hs0003 50151 | Chapel Hill | North Carolina | 27516 | — |
| Hs0003 50177 | Cincinnati | Ohio | 45219 | — |
| Hs0003 50138 | Columbus | Ohio | 43213 | — |
| Hs0003 50204 | Tulsa | Oklahoma | 74135 | — |
| Hs0003 50147 | Hershey | Pennsylvania | 17033 | — |
| Hs0003 50008 | Johnston | Rhode Island | 02919 | — |
| Hs0003 50180 | Providence | Rhode Island | 02903 | — |
| Hs0003 50142 | Nashville | Tennessee | 37215 | — |
| Hs0003 50201 | Arlington | Texas | 76011 | — |
| Hs0003 50166 | Dallas | Texas | 75246 | — |
| Hs0003 50149 | San Antonio | Texas | 78213 | — |
| Hs0003 50270 | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04242446, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04242446 live on ClinicalTrials.gov.